Arteriovenous malformation vasculature (AVM vasculature)

Arteriovenous malformation vasculature" refers to the abnormal network of blood vessels found in an arteriovenous malformation (AVM), which is a tangled cluster of arteries and veins directly connected without the normal intervening capillaries. This atypical vasculature disrupts blood flow, causes tissues to be deprived of oxygen, and exposes vessels to higher pressure than normal, potentially resulting in rupture, bleeding, and severe neurological or tissue damage. AVMs are usually congenital but can present later in life and are most clinically significant when occurring in the brain or spinal cord, where they may cause hemorrhage, seizures, or stroke. Key context and clarification: "Arteriovenous malformation vasculature" is not a canonical molecular target (such as a protein, receptor, enzyme, etc.) but instead describes an abnormal blood vessel network—a *pathological tissue structure* rather than a specific molecule or therapeutic target. No specific drugs are known to interact directly with "AVM vasculature" as a molecular target. Treatments are procedural (surgery, embolization, radiosurgery), not pharmacological antagonists or agonists of a discrete molecular entity. This label ("Arteriovenous malformation vasculature") is considered incorrect as a molecular target for drug discovery or therapeutic databases; it should instead refer to specific molecules (e.g., proteins, growth factors, or receptors) involved in AVM pathophysiology if druggable targets are sought. The current term refers to a vascular anomaly, not a molecular entity.

Other names

Arteriovenous malformationAVMAVM vasculatureArteriovenous malformations